Disposition of 8637 shares by Megna Michael R of Kiniksa Pharmaceuticals at 11.1 subject to Rule 16b-3
KNSA Stock | USD 19.88 0.78 3.78% |
About 62% of Kiniksa Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Kiniksa Pharmaceuticals suggests that many traders are alarmed. The current market sentiment, together with Kiniksa Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Kiniksa Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Kiniksa |
Filed transaction by Kiniksa Pharmaceuticals Officer: Chief Accounting Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Kiniksa Pharmaceuticals Fundamental Analysis
We analyze Kiniksa Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kiniksa Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kiniksa Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Target Price
Target Price Comparative Analysis
Kiniksa Pharmaceuticals is currently under evaluation in target price category among its peers.
Kiniksa Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kiniksa Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Kiniksa Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Kiniksa Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Kiniksa Pharmaceuticals Related Equities
CHRS | Coherus BioSciences | 10.66 | ||||
COGT | Cogent Biosciences | 3.44 | ||||
GOSS | Gossamer Bio | 3.13 | ||||
REPL | Replimune | 2.64 | ||||
SPRO | Spero Therapeutics | 1.16 | ||||
ACLX | Arcellx | 0.81 | ||||
NVCT | Nuvectis Pharma | 0.30 | ||||
GPCR | Structure Therapeutics | 1.15 | ||||
KURA | Kura Oncology | 1.49 | ||||
KRON | Kronos Bio | 1.94 | ||||
VTYX | Ventyx Biosciences | 1.95 | ||||
BOLT | Bolt Biotherapeutics | 2.00 | ||||
NUVL | Nuvalent | 2.21 | ||||
LRMR | Larimar Therapeutics | 3.27 | ||||
DAWN | Day One | 3.81 | ||||
CGEM | Cullinan Oncology | 3.83 | ||||
LYRA | Lyra Therapeutics | 5.26 | ||||
PHAT | Phathom Pharmaceuticals | 5.52 |
Complementary Tools for Kiniksa Stock analysis
When running Kiniksa Pharmaceuticals' price analysis, check to measure Kiniksa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiniksa Pharmaceuticals is operating at the current time. Most of Kiniksa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiniksa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiniksa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiniksa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum |